Genflow Biosciences trial meets primary endpoint in aged dogs
Genflow Biosciences PLC reports that its SLAB (Sarcopenia and Longevity in Aged Beagles) randomized, blinded trial of its SIRT6 centenarian gene therapy met the primary endpoint of reduced biological age measured by the GRIM methylation clock. The study enrolled 24 beagle dogs older than 10 years, a
<p>Genflow Biosciences PLC reports that its SLAB (Sarcopenia and Longevity in Aged Beagles) randomized, blinded trial of its SIRT6 centenarian gene therapy met the primary endpoint of reduced biological age measured by the GRIM methylation clock. The study enrolled 24 beagle dogs older than 10 years, a</p>